title: Toxicity of weekly oral topotecan in relation to dosage for gynecologic malignancies:  a phase I study.
abstract: The aim of this study was to determine the dose of weekly oral topotecan that allows safe administration and to evaluate the pharmacokinetics of this dose in patients with recurrent gynecologic malignancies. The first cohort of patients received oral topotecan 6 mg/week administered orally on days 1, 8, and 15 of a 28-day regimen. A standard 3+3 dose-escalating phase design was used for dose levels II-V (8, 10, 12 and 14 mg/week). Toxicity was scored according to the Common Terminology Criteria for Adverse Events. Cumulative toxicity was summarized in the 6-12 mg/week combined cohort and 14 mg/week cohort separately. Pharmacokinetic samples were obtained for day 1, cycle 1 only in the expansion cohort (dose level V). Twenty-five patients received a total of 88 cycles of therapy. Hematologic toxicities of grade 3 (6-12 mg dose) were neutropenia (25%) and anemia (8.3%). Gastrointestinal toxicities of grade 3 were diarrhea (16.7%) and obstruction (8.3%, disease-related). Grade 3 or 4 (14 mg/week) hematologic toxicities consisted of neutropenia (38.5%), platelets (15.4%), anemia (15.4%), infection with neutropenia (7.7%), and thrombosis (7.7%). Gastrointestinal toxicities of grade 3 were diarrhea (7.7%), obstruction (7.7%), and vomiting (7.7%). One patient died secondary to neutropenic sepsis. One patient (4%; 95% confidence interval: 2.1, 22.3) showed a partial response and five patients (20%; 95% confidence interval: 7.6, 41.3) had stable disease. An oral topotecan dose of 14 mg/week for 3 consecutive weeks out of 4 is mostly associated with acceptable toxicities and may be considered for use in future single-agent phase II trials.
authors.affiliation: Department of Obstetrics & Gynecology, Summa Akron City Hospital, Akron, Ohio 44309, USA. vongruev@summahealth.org
authors.forename: Vivian E
authors.initials: VE
authors.lastname: von Gruenigen
authors.forename: Heidi E
authors.initials: HE
authors.lastname: Frasure
authors.forename: Deborah A
authors.initials: DA
authors.lastname: Smith
authors.forename: Nancy L
authors.initials: NL
authors.lastname: Fusco
authors.forename: Susan M
authors.initials: SM
authors.lastname: Eaton
authors.forename: Robert L
authors.initials: RL
authors.lastname: DeBernardo
authors.forename: Anne M
authors.initials: AM
authors.lastname: Heugel
authors.forename: Steven E
authors.initials: SE
authors.lastname: Waggoner
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000139:chemically induced; D015331:Cohort Studies; D003967:Diarrhea / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D059004:Topoisomerase I Inhibitors / Q000627:therapeutic use* / Q000633:toxicity; D019772:Topotecan / Q000627:therapeutic use* / Q000633:toxicity; D014594:Uterine Neoplasms / Q000188:drug therapy*
chemical_list: D059004:Topoisomerase I Inhibitors; D019772:Topotecan